Corticosteroid-Eluting Sinus Stents tied to post operative infections, Finds study

According to recent research, investigators have found out that there are certain adverse events associated with corticosteroid-Eluting Sinus Stents out of which the most commonly reported include postoperative infection, including multiple cases of fungal infection, followed by migration of the stent.

The study is published in the SAGE Journals.

Corticosteroid-eluting stents (CESs) are increasingly used after endoscopic sinus surgery to reduce the need for revision surgery, but their use is not without risks.

Therefore, Vishal Narwani and colleagues from the

Division of Otolaryngology, Department of Surgery, School of Medicine, Yale University, New Haven, Connecticut, USA conducted the present study to describe adverse events related to CESs.

The authors carried out a retrospective cross-sectional study. The US Food and Drug Administration's MAUDE database was queried for reports of adverse events involving the use of CESs approved by the Food and Drug Administration, including Propel, Propel Mini, Propel Contour, and Sinuva.

The following were results reported-

a. There were 28 reported adverse events in total, with all events being related to the Propel family of stents and none related to Sinuva stents.

b. Overall, 22 were categorized as patient-related adverse events and 6 as device-related events.

c. The most common adverse event was related to postoperative infection, accounting for 39% (n = 11) of all complications.

d. Four of these patients developed periorbital cellulitis, and 5 developed a fungal infection.

e. The second-most common adverse event was migration of the stent, representing 21% of all complications (n = 6).

f. Overall, 8 patients (29%) in our cohort required reintervention in the operating room, with subsequent removal of the CES.

Hence, it was concluded that "The most commonly reported adverse events were postoperative infection, including multiple cases of fungal infection, followed by migration of the stent."

However, an increased awareness of the complications associated with CESs can be used to better inform patients during the consenting process as well as surgeons in their surgical decision making, they said.